CBI wants Shehla Masood murder case to be tried in Indore

June 12, 2012

ShehlaNew Delhi, June 12: Central Bureau of Investigation (CBI) on Monday opposed the plea of the five accused in RTI activist Shehla Masood murder case to transfer the case to Bhopal under section 177 of CrPC before the special CBI court. Accused Zaheda Parvez, her accomplice Saba Farooqui, history-sheeter Saquib 'Danger,' shooters Irfaan Ali and Tabish Khan were produced before the judge Dr Shubhra Singh.

CBI counsel Hemant Shukla said, CBI special court of Indore has power and jurisdiction to hear the case and that the case should not be transferred to Bhopal. To supplement his argument he gave four instances including one that of 2003 Madhya Pradesh High Court where the cases were heard by the special court away from the place of crime. Shukla argued that section 14 (3) of CrPC 1978 has amended section 177 and empowered the special court to hear cases. In this case, as initial hearing was held in Indore and charge-sheet was also filed here, the trial should also be continued in Indore.

However, the defense counsel of all the accused together argued that under section 177 of CrPc, hearing of the case should be held in the place of crime. "Crime was committed in Bhopal, investigation took place in Bhopal, all the witnesses are from Bhopal so the case should also be shifted to that city as per the law," said defense lawyer Sunil Shirivastav adding that the families of accused are staying in Bhopal and they have to face inconvenience. He stressed that there are certain things beyond law which need to be considered on humanitarian grounds.

Another defense lawyer Y Khan said that several cases are registered against some of the accused in Bhopal and their families too stay in the state capital. Thus, for the convenience of the accused, the court hearing should be shifted to state capital, he reasoned. In his reply, the defense lawyers sought time from the court and will present their argument during the next hearing scheduled for Friday, June 15.

Advocate Memon to appeal for re-investigation

Bagish K Jha

In a new twist to Shehla Masood murder case, the father of slain RTI activist, Sultan Masood, have contested the charge-sheet filed by the CBI. He met famous criminal lawyer advocate Majeed Memon in Mumbai recently with a copy of charge-sheet and alleged that the investigating agency had been protecting BJP MLA Dhruvnarayan Singh and wanted the case to be re-investigated by other officials. The MLA's name came up several times in the course of investigation and had to undergo lie-detector test following allegations against him in the case.

Talking to TOI over phone from Mumbai, advocate Memon said he would appear before the court on behalf of the Masood family and appeal to re-investigate the case. It is not a matter of a family, but is related to the security of common man and the matter of law and order in Madhya Pradesh, he said.

It seems that the CBI has investigated the case with a view to protecting Dhruvnarayan, who was central character in entire episode, but was not even listed as the witness in the charge-sheet.

More than 145 witnesses have been enlisted in the charge-sheet by the CBI. "Beside this, the call details of Shehla were not submitted to the court which could have thrown light on the case," Memon said.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
Agencies
July 2,2020

New Delhi, Jul 2: In the midst of India's tense border standoff with China, the defence ministry on Thursday approved procurement of a number of frontline fighter jets, missile systems and other platforms at a cost of Rs 38,900 crore to bolster the combat capability of the armed forces, officials said.

They said 21 MiG-29 fighter jets are being bought from Russia while 12 Su-30 MKI aircraft will be procured from Russia. The ministry has also approved a separate proposal to upgrade existing 59 MiG-29 aircraft.

The decisions were taken at a meeting of the Defence Acquisition Council (DAC) chaired by Defence Minister Rajnath Singh.

The procurement of 21 MiG-29 and upgrading of the existing fleet of MiG-29 are estimated to cost the government Rs 7,418 crore while purchase of 12 new Su-30 MKI from the Hindustan Aeronautics Ltd will be made at a cost of Rs 10,730 crore, the officials said.

The DAC also approved procurement of long-range land-attack cruise missile systems with a range of 1,000 KM and Astra Missiles for Navy and Air Force.

The officials said cost of these design and development proposals is in the range of Rs 20,400 crore.

"While acquisition of Pinaka missile systems will enable raising additional regiments over and above the ones already inducted, addition of long-range land attack missile systems having a firing range of 1000 KM to the existing arsenal will bolster the attack capabilities of the Navy and the Air Force," said a defence ministry official.

"Similarly induction of Astra Missiles having beyond visual range capability will serve as a force multiplier and immensely add to the strike capability of the Indian Navy and the Indian Air Force," he said.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
May 28,2020

May 28: Congress President Sonia Gandhi on Thursday asked the central government to unlock its coffers and help the needy affected by the coronavirus-induced lockdown.

In a video message posted as part of the Congress' 'Speak Up India' campaign, she lamented that even though the country is passing through a serious economic crisis with loss of livelihood due to the pandemic and the lockdown, the central government has not heard the cries of pain and trauma of people.

"We again urge the Centre to unlock its coffers and help the needy. Put direct cash of Rs 7,500 per month in the account of every family for the next six months and provide Rs 10,000 immediately; ensure safe and free travel of labourers back home, employment opportunity and rations; and also increase the number of work days under MNREGA to 200 days to facilitate jobs in villages," Gandhi said.

"Instead of loans, provide financial relief to small and medium industry so that crores of jobs are saved and the country progresses," she said in her video message on the party's social media handles.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
June 25,2020

New Delhi, Jun 25: After the Drug Controller General of India (DCGI) given its approval to manufacture and market the generic version of COVID-19 drug Remdesivir, COVIFOR, Hyderabad-based drugmaker Hetero Limited has delivered the first set of 20,000 vials in two equal lots of 10,000 each across 5 states.

The first batch, which is being marketed under the brand name of COVIFOR, was delivered to Maharashtra, Delhi, Gujarat Tamil Nadu and Hyderabad. Hetero has set a target to produce one lakh vials of the drug in two-three weeks.

The other lot would be supplied to Kolkata, Indore, Bhopal, Lucknow, Patna, Bhubaneshwar, Ranchi, Vijayawada, Cochin, Trivandrum and Goa within a week to meet the emergency requirements.

Managing director of Hetero Healthcare M Srinivasa Reddy said “the launch of Covifor in the country is a milestone in addressing public health emergencies. Through Covifor, we hope to reduce the treatment time of a patient in a hospital thereby reducing the increasing pressure on the medical infrastructure overburdened ue to accelerating COVID-19 infection rates," he said as reported by news agency.

"We are closely working with the government and the medical community to make Covifor quickly accessible to both public and private healthcare settings across the country”, Reddy said.

Covifor is a generic brand of Remdesivir which is used for the treatment of COVID-19 in adults and children hospitalised with strong symptoms of the disease. The Health Ministry had, on June 13, recommended the use of anti-viral drug Remdesivir in moderate stage of COVID-19.

Dr Reddys Laboratories and Hetero are among others which have separately entered into non-exclusive licensing agreements with the original drug-maker Gilead Sciences Inc to register, make and sell the investigational drug Remdesivir in India and other countries.

Remdesivir would be made in the company's formulation facility in Hyderabad, which has been approved by global regulatory authorities such as US Food and Drug Administration (USFDA) and EU, among others, Hetero had earlier said.

The treatment first showed improvement in trials on coronavirus patients and was approved for emergency use in severely ill patients in the United States and South Korea.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.